April 9th, 2013
The TACT Investigators Respond to Questions
Gervasio Antonio Lamas, MD, Daniel Mark, Christine Goertz, DC, PhD, Robin Boineau, M.D., M.A., Kerry L. Lee, Ph.D. and Harlan M. Krumholz, MD, SM
The publication in JAMA of the NIH’s Trial to Assess Chelation Therapy (TACT) has reignited a heated debate about the trial. The TACT investigators have generously agreed to respond to questions posed by Harlan Krumholz.
April 8th, 2013
Selections from Richard Lehman’s Literature Review: April 8th
Richard Lehman, BM, BCh, MRCGP
This week’s topics include an article on open science through data sharing, primary prevention of CVD with a Mediterranean diet, atherosclerosis found in mummies, and more.
April 7th, 2013
Researchers Find New Pathway Linking Heart Disease To Carnitine
Larry Husten, PHD
A new line of preliminary research has turned up a novel pathway linking atherosclerosis to red meat and a common supplement contained in energy drinks. If the research is upheld, the findings may have important implications for dietary recommendations and our understanding of atherosclerosis. The research also provides another quite surprising example of the previously […]
April 5th, 2013
Cardio-Oncology: Who Needs It?
John Ryan, MD
Our panel sketches out the scope of this growing discipline.
April 5th, 2013
Are Adults with Congenital Heart Disease Falling Off the Radar?
Michelle Gurvitz, MD MS and John Ryan, MD
A new study characterizes the gaps in care that patients with congenital heart disease experience as they move from adolescence to adulthood.
April 4th, 2013
Registry Study Offers Reassurance About Safety and Efficacy of Dabigatran
Larry Husten, PHD
As the first new oral anticoagulant since warfarin, dabigatran (Pradaxa, Boehringer-Ingelheim) has been subject to intense concerns over its safety and efficacy in a real-world population. Last November an FDA investigation found no indication that bleeding rates for dabigatran were any higher than bleeding rates for warfarin. A new study from Scandinavia, published in the Journal of the American […]
April 3rd, 2013
International Cardiovascular Device Registries: The Next Big Thing
Larry Husten, PHD
A new initiative involving a wide variety of stakeholders — the FDA, the American College of Cardiology, the Society of Thoracic Surgeons, industry, medical journals, and others — could lead to an enormous international cooperative effort to make device registries a standard part of the practice of cardiology. This will be a “huge step,” said David […]
April 2nd, 2013
Lifelong Statin Sentence Now Includes Furloughs
Larry Husten, PHD
Although the benefits of statins are among the best documented in all of medicine, continuous lifelong statin therapy is not always easy to achieve in clinical practice. Now a new retrospective study suggests that although clinical events causing temporary cessation of statin therapy occur often, most of these patients are later able to resume statin […]
April 2nd, 2013
Selections from Richard Lehman’s Literature Review: April 2nd
Richard Lehman, BM, BCh, MRCGP
This week’s topics include the TACT study of chelation therapy, off-pump vs. on-pump CABG, clopidogrel with or without aspirin in those taking oral anticoagulants and undergoing PCI, and more.
April 2nd, 2013
Intensive Glucose Control and ESRD – Strongest Evidence?
Kasia Lipska, MD, MHS
Kasia Lipska unpacks a report in Kidney International that claims to provide “the strongest evidence yet” of a protective effect of intensive glucose lowering against end-stage renal disease in type 2 diabetes.
NEJM Journal Watch — Recent Cardiology Articles- Oral Semaglutide Approved to Lower Cardiovascular Risk in High-Risk Patients with Type 2 Diabetes
- Covid-19 Vaccines Improve Heart Outcomes
- Detecting Atrial Fibrillation After Transient In-Hospital Episodes
- Cardiac Involvement with Mycoplasma pneumonia: More Common Than Previously Thought
- Amyloid in the Heart